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PoxvirusVaccinia virus (VACV), the vaccine for smallpox, induces an antibody response that is largely responsible for
conferring protection. Here, we studied the antibody response to VACV by generating and characterizing B cell
hybridomas from a mouse immunized with VACV. Antibodies from 66 hybridomas were found to recognize
11 VACV antigens (D8, A14, WR148, D13, H3, A56, A33, C3, B5, A10 and F13), 10 of which were previously
recognized as major antigens in smallpox vaccine by a microarray of VACV proteins produced with a
prokaryotic expression system. VACV C3 protein, which was not detected as a target of antibody response by
the proteome array, was recognized by two hybridomas, suggesting that selection of hybridomas based on
immune recognition of infected cells has the advantage of detecting additional antibody response to native
VACV antigens. In addition, these monoclonal antibodies are valuable reagents for studying poxvirus biology
and protective mechanism of smallpox vaccine.d at fax: +1 210 567 0293.
iangy@uthscsa.edu (Y. Xiang).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Vaccinia virus (VACV), a member of the Orthopoxvirus genus of the
Poxviridae family (Moss, 2007), serves as the live vaccine against
smallpox, which is caused by another orthopoxvirus, variola virus
(Damon, 2007). As a vaccine, VACV is one of the most successful in
human history, responsible for eradicating smallpox from nature. Live
VACV immunization elicits robust antibody and cytotoxic T cell
responses that persist for decades in humans (Crotty et al., 2003;
Hammarlund et al., 2003; Putz et al., 2005; Viner and Isaacs, 2005). In
animal models, the antibody response alone is sufﬁcient to protect
against diseases caused by pathogenic orthopoxviruses, although the
cytotoxic T cell response also contributes to the immune protection
(Belyakov et al., 2003; Panchanathan et al., 2008).
VACV produces two different infectious virion forms (Condit et al.,
2006; Smith et al., 2002), both of which are targets of antibody response
in smallpox vaccine. The majority of the infectious VACV are the
intracellular mature viruses (MV), which remain inside cells until cell
lysis.MVhas amembrane that is associatedwith at least 19different viral
proteins (Condit et al., 2006). Among them, A27 (Rodriguez et al., 1985),
L1 (Ichihashi and Oie, 1996; Wolffe et al., 1995), D8 (Hsiao et al., 1999),
H3 (Davies et al., 2005b) and A28 (Nelson et al., 2008) are known to be
the targets of neutralizing antibodies. A small fraction of MV in the cells
gain additional membranes through wrapping with Golgi cisternae
(Smith et al., 2002). They are eventually released through exocytosis asthe extracellular enveloped viruses (EV), which are responsible for long-
range spread of the virus within the host. EV has one additional outer
membrane than MV, which is associated with at least 6 different viral
proteins (Smith et al., 2002). Among them, B5 is the major target of
neutralization antibodies (Bell et al., 2004;Benhnia et al., 2009; Putz et al.,
2006), while A33 is known to elicit protective antibody response
(Galmiche et al., 1999). For optimal immuneprotection against smallpox,
antibodies against both MV and EV are required (Smith et al., 2002).
In response to a renewed interest in developing a safer smallpox
vaccine, studies were recently carried out to systematically charac-
terize the immune responses to VACV following VACV immunization.
A large number of CD4+ and CD8+ T cell epitopes were discovered in
VACV (Moutaftsi et al., 2006; Oseroff et al., 2005; Sette et al., 2008;
Tscharke et al., 2005; Tscharke et al., 2006). In addition, the antibody
response to VACVwas proﬁled with a proteomemicroarray consisting
of recombinant VACV proteins that were produced with a prokaryotic
expression system (Davies et al., 2005a, 2007, 2008). The array
consistently detected antibodies to 25 VACV proteins, the majority of
which are virion components and belong to the late class of viral
proteins (Davies et al., 2007). In our current studies, we developed
and characterized a large panel of B cell hybridomas from a mouse
immunized with VACV. The spectrum of the monoclonal antibodies
that we generated matched nicely with the polyclonal antibody
proﬁle obtained with the proteome microarray. In addition, we found
antibodies to a VACV antigen that was not previously found with the
microarray. More importantly, our study resulted in monoclonal
antibodies against a wide variety of VACV antigens, which could be
used to study B cell epitopes in smallpox vaccine. These antibodies are
also valuable research reagents for studying VACV biology, as some
272 X. Meng et al. / Virology 409 (2011) 271–279represent the ﬁrst-ever monoclonal antibodies against several
important VACV membrane and core proteins.
Results
Generation and selection of B cell hybridomas speciﬁc for VACV
A BALB/c mouse was infected intranasally with an attenuated
VACV mutant, eliciting an immune response that was able to protectJA11 (group 1(D8)) GH3 (group2(A14
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Fig. 1. Screen for murine hybridomas that secret anti-VACV antibodies with an immunoﬂuor
0.1 to 0.5 PFU/cell for 8 h and then analyzed by immunoﬂuorescence with hybridoma cultu
Cy3-conjugated goat anti-mouse secondary antibody (red), and the DNA was stained with
infected cells, which display viral DNA factories as areas of cytoplasmic DNA staining. Imag
name. Shown in parenthesis is the group that the hybridoma was subsequently categorizedthe mouse against a subsequent high dose intranasal challenge of the
wild type (WT) VACVWR. As we were interested in developing some
monoclonal antibodies speciﬁc for VACV, this hyperimmune mouse
was then boosted with an intravenous injection of UV-inactivatedWT
VACV and, three days later, its spleen was harvested for hybridoma
generation. The hybridomas were screened for their speciﬁcity for
VACVwith an immunoﬂuorescence assay, in whichWR-infected HeLa
cells were stained with culture supernatants of the hybridomas. The
HeLa cells had been infected for 8 h at amultiplicity of infection (MOI)HE7 (group3(WR148))))
LC10 (group6(A56))
LA10 (group9(B5))
3))
VF
F
V
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escence assay. HeLa cells grown on cover-slips were infected with VACVWR at a MOI of
re supernatants as the primary antibodies. The primary antibodies were stained with a
DAPI (blue). Speciﬁcity of the antibody to VACV is indicated by staining of only WR-
es obtained with 11 representative hybridomas are shown with the hybridoma clone
into. Arrows point to viral factories (VF), virion-size particles (V) and aggregates (A).
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as infected cells with all temporal classes of VACV proteins could
be stained together with the antibodies. Hybridomas were deemed
speciﬁc for VACV if their culture supernatant stained only WR-
infected cells, which displayed viral DNA factories as areas of
cytoplasmic DNA staining (Fig. 1). Approximately 100 hybridomas
that were repeatedly positive for VACV by immunoﬂuorescence
assay were kept. Around 25 ml culture supernatant was collected
from each hybridoma for subsequent analysis.
Several distinct immunoﬂuorescence patterns were observed
during the initial screening (Fig. 1), and they were used later to
categorize the hybridomas and corroborate with antigen identiﬁca-
tion (Table 1). Immunoﬂuorescence with JA11 (group 1) and JH4
(group 5) stained viral factories, additional areas outside viral
factories and many virion-size particles, indicating that their targets
may be abundant proteins on the surface of MV (Fig. 1). GH3 (group
2), AD4 (group 4) and BG3 (group 10) also stained the viral factories,
indicating that their targets are proteins involved in MV assembly.
While GH3 (group 2) exclusively stained viral factories, BG3 (group
10) also stained some virion-size particles, and AD4 (group 4) also
stained some aggregates that were signiﬁcantly bigger than virion
particles. The nature and biological signiﬁcance of the aggregates are
unclear. The relatively smaller factories in some cells were not stained
with the above-mentioned antibodies, perhaps because they
were newly formed factories in cells that had been infected for a
shorter period of time. KA10 (group 7), AF9 (group 8), LA10 (group 9)
and CE7 (group 11) predominantly stained areas outside the
viral factories, suggesting that their targets are not involved in MV
assembly. In addition, LA10 (group 9) and CE7 (group 11) also stained
virion-size particles, indicating that their targets may be on the
surface of EV. HE7 (group3) stained the entire cytoplasm very evenly,
while LC10 (group6) appeared to stain the outline of the infected cells.
Categorization of the hybridomas according to molecular weight (MW)
of the immunoprecipitated proteins
We further characterized the hybridomas by using their culture
supernatants to precipitate proteins from VACV-infected cells. HeLaTable 1
A panel of murine monoclonal antibodies against vaccinia virus.
Group # Clone namea Immunoﬂuor
1 IgG1: AB12(WB++),CC7, JF11 Factory; som
IgG2a:JE10,JE11,EE11,BF1,EB2,JA11,FH4,HG12,LA5,JE4
IgG2b:BH7,BG9,CF10,BD6
Nd: KF4
2 IgG1: BF8,HE6 Factory
IgG2b: FE11
IgG3: LB8,GH3 (WB++), DF8,AD10
Nd: KD8,LE11,TH6,BB5, CE11,JG8, BF9,AD5,JE1, AG12
3 IgG2a: HE7(WB++),DF5,BA7 Entire cytopla
IgG2b: CB9
Nd:AG6,AF10,BB1,GB10,CG3,CG6,CA2, FD4,CF3
4 IgG2b: AD4 (WB−) Factory, aggre
Nd: AB10, AE5,KB1,HD9,FG5,GB11
5 IgG1: AE11 Factory; som
IgG2a: JH4 (WB−)
6 IgG1: LC10 (WB+) Cell surface
Nd: BE2
7 IgG2a:KA10 (WB++) Outside facto
Nd: LA11
8 IgG1:AF9 (WB−) Outside facto
Nd: JB11
9 IgG2b: LA10 (WB−) Outside facto
10 IgG1: BG3 (WB+) Factory, parti
11 IgG2a: CE7 (WB−) Outside facto
a The isotypes of the clones are shown in italics and underlining. Nd: isotype not determin
Western blot (WB) and the results are shown in parenthesis. WB++: positive in WB; WB+
b Factory: staining predominantly of viral DNA factory; and outside factory: staining pre
c Molecular weight (MW) was calculated from mobility of the protein relative to molecucells were infected with VACV WR at a MOI of 10 for 8 h and then
metabolically-labeled with 35S-methionine and -cysteine for another
8 h. Cell lysates were prepared and subjected to immunoprecipitation
with the hybridoma supernatants. SDS-PAGE of the precipitates
showed that the supernatants of 66 hybridomas pulled down speciﬁc
proteins from VACV-infected cells (Fig. 2 and data not shown). The
rest of the hybridomas did not pull down any protein (data not
shown), and they were not characterized further. Hybridomas
that pulled down VACV proteins can be categorized into 11 groups
according to the apparent MW of the precipitated protein and the
immunoﬂuorescence pattern (Table 1). For example, group 1 of 18
hybridomas, including JA11, precipitated a single protein with an
apparent MW of 30 kDa by SDS-PAGE (Fig. 2). In addition, they all
stained virion-size particles in immunoﬂuorescence (Fig. 1), indicat-
ing they might recognize the same antigen.
Identiﬁcation of the antigens recognized by the hybridomas
We identiﬁed the antigens that were recognized by the hybrid-
omas with a variety of methods, which are described separately for
each hybridoma group.
Identiﬁcation of the antigen with antigen-speciﬁc rabbit antiserum
Group 1(D8). 18 hybridomas of group 1 precipitated a protein with an
apparent MW of 30 kDa (Fig. 2), and stained viral factories and virion-
size particles in immunoﬂuorescence (Fig. 1). As MV structural
proteins usually localize to viral DNA factories during VACV infection,
the immunoﬂuorescence of group 1 hybridomas suggested that the
antigenmight be aMVmembrane protein such as D8 (theoretical MW
of 35 kDa) or L1 (theoretical MW of 27 kDa). We therefore used anti-
D8 and anti-L1 rabbit antisera to test whether the precipitated antigen
was D8 or L1. In a Western blot analysis, D8 antiserum (Sakhatskyy
et al., 2006), but not L1 antiserum (not shown), speciﬁcally recog-
nized the antigen that was precipitated by these 18 hybridomas and
resolved by SDS-PAGE in the absence of any reducing agent (Fig. 3A
and data not shown). The D8 antiserum also recognized a protein
with an apparent MW of 67 kDa, which disappeared upon theescence patternb MW by SDS-PAGEc Antigen
e outside factory; virion-size particles 30 D8(WR113)
15,23 A14(WR133)
sm 87 WR148
gates 61 D13(WR118)
e outside factory; virion-size particles 32 H3(WR101)
79 A56(WR181)
ry 22 A33(WR156)
ry 27 C3(WR025)
ry, virion-size particles 40 B5(WR187)
cles 93 A10(WR129)
ry, virion-size particles 38 F13(WR052)
ed. A representative clone of each group was tested for its ability to recognize antigen in
: weak positive in WB; and WB−: negative in WB.
dominantly of areas outside viral DNA factory.
lar weight standards on SDS-PAGE by using the Bio-rad quantity one program.
Fig. 2. Categorization of the hybridomas into 11 groups according to the apparent molecular weight of the precipitated protein. HeLa cells were infected with VACVWR at aMOI of 10
and metabolically-labeled with 35S-methionine and -cysteine from 8 to 16 hpi. The cells were lyzed and immunoprecipitated with the hybridoma supernatants and Protein G
sepharose. The precipitated proteinswere analyzed by SDS-PAGE, and the autoradiographs of representative samples are shown. The results are grouped together according to the size
of the precipitated proteins and are shown from the smallest to the largest precipitated proteins. Shown above each lane is the clone name of the hybridoma whose supernatant was
used for the immunoprecipitation. The control immunoprecipitation with DMEM-10 medium is indicated by “–”. The group number of the hybridomas is indicated below the lanes.
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linked D8 dimer. Protein ﬁnger-printing with mass spectrometry
also conﬁrmed that the antigen precipitated by this group of
hybridomas is indeed D8 protein (data not shown).
To further conﬁrm if group 1 hybridomas are speciﬁc for D8, we
performed Western blot on recombinant GST fusion protein of D8. As
shown in Fig. 4A, AB12 speciﬁcally recognized GST-D8 fusion protein
among the bacterial cell lysate, indicating that its target is D8. AB12
also recognized the D8 protein in infected cells and in puriﬁed MV
virions in a Western blot (Fig. 4B).
Group 9(B5). LA10 precipitated a protein with an apparent MW of
40 kDa (Fig. 2). Immunoﬂuorescencewith LA10 showed strong staining
of virion-size particles as well as areas outside the viral DNA factories
(Fig. 1). As EVmembrane proteins usually localize toGolgi insteadof the
viral factories, the immunoﬂuorescence of LA10 indicated that the target
of LA10 may be an EV membrane protein such as B5 (theoretical
MW of 42 kDa). Rabbit anti-B5 antiserum (Sakhatskyy et al., 2006)
recognized the antigen that was precipitated by LA10 in aWestern blot
(Fig. 3A). As a control, B5 antiserum did not recognize the antigens that
were precipitated by three other hybridomas of groups 5, 8 and13.Mass
spectrometry analysis of the antigen precipitated by LA10 conﬁrmed
that the antigenwas indeedB5protein (Fig. 3C). LC10 failed to recognize
B5 in infected cells in Western blot (data not shown), suggesting that
it recognizes a conformational epitope.
Identiﬁcation of the antigen with gene-speciﬁc deletion mutants of VACV
Group 3(WR148). A large group of 13 hybridomas, including HE7,
precipitated a protein with an apparent MW of 87 kDa and stronglystained the entire cytoplasm in immunoﬂuorescence (Figs. 1 and 2).
WR148 (theoretical MW of 84 kDa) was recently reported to be an
immunodominant antigen in smallpox vaccine (Davies et al., 2007),
so we tested whether WR148 is the target of these hybridomas by
using a WR mutant that is speciﬁcally deleted of WR148 (Jones-
Trower et al., 2005). As shown by a Western blot in Fig. 3B, HE7
recognized an antigen that was present in WT WR-infected cells by
not in ΔWR148-infected cells, indicating that its target is WR148. The
cells were infected equally by the two viruses, as a similar amount
of D8 was detected in both samples. HE7 also speciﬁcally recognized a
recombinant GST fusion protein of WR148 among the bacterial
cell lysates in Western blot (Fig. 4A).
Group 6(A56). LC10 and BE2 precipitated a protein that ran as a broad
band with an apparent MW of 79 kDa (Fig. 2), suggesting that these
two hybridomas recognize a viral glycoprotein. We considered A56 as
the most likely target among the few glycoproteins expressed by
VACV, as A56 was reported to migrate as 85/89 kDa on SDS-PAGE
(Payne, 1979; Shida and Dales, 1981). Indeed, LC10 recognized an
antigen that was present in WT WR-infected cells but not in cells
infected by an A56 deletion mutant (Fig. 3B). In addition, LC10
speciﬁcally recognized a recombinant GST fusion protein of A56
among the bacterial cell lysates in Western blot (Fig. 4A). LC10 and
BE2 stained the outline of the infected cells in immunoﬂuorescence
(Fig. 1), which is consistent with previous reports that A56 is
predominantly distributed on cell surface (Lorenzo et al., 2000).
Group 7(A33). Immunoﬂuorescence with KA10 and LA11 stained
areas outside viral factories (Fig. 1), suggesting that the target might
be an EV membrane protein. KA10 and LA11 precipitated a protein
Fig. 3. Identiﬁcation of the antigenic targets of the hybridomas. (A) Identiﬁcation of hybridoma speciﬁc for VACV D8 or B5 with rabbit antisera against D8 or B5. Culture supernatants
from the indicated hybridomas were used to immunoprecipitate proteins fromWR-infected HeLa cells. The precipitated proteins were resolved by SDS-PAGE in the absence of any
reducing agent and analyzed byWestern blot with the indicated rabbit antisera (D8 or B5). (B) Identiﬁcation of hybridoma speciﬁc for WR148, A56 or A33 with WRmutant deleted
of the speciﬁc gene. Proteins from uninfected (Un) cells or cells infected with the indicated WR virus (WT, ΔWR148, ΔA56R or ΔA33R) were resolved by SDS-PAGE and analyzed by
Western blot using supernatants from the indicated hybridomas. The same membranes were also blotted with rabbit antiserum against D8 as a control for loading of viral proteins.
(C) Identiﬁcation of the antigen by mass spectrometry analysis. Proteins from uninfected cells (−) or WR-infected cells (+ or not indicated) were immunoprecipitated with the
indicated antibodies. Except for JH4 and LA10, all other antibodies were conjugated to Protein G sepharose with a crosslinker. Coomassie stains of the precipitated proteins after SDS-
PAGE separation are shown. Speciﬁc bands (boxed and numbered from 1 to 7) were cut off the gel, digested with trypsin and analyzed with mass spectrometry, the result of which is
shown in the table below.
275X. Meng et al. / Virology 409 (2011) 271–279that ran as a broad band with an apparent MW of 22 kDa (Fig. 2),
further suggesting that they may recognize a viral glycoprotein of EV
membrane such as A33 (theoretical MW of 21 kDa) or A34(theoretical MW of 20 kDa). They recognized an antigen that was
present in WT WR-infected cells but not in cells infected by an A33
deletion mutant (Roper et al., 1998) in a Western blot (Fig. 3B and
Fig. 4. Conﬁrmationof theantigenic targets of thehybridomas. (A)Westernblot of recombinantGST fusionproteins. E. coli. strainswere eithernot induced (−) or inducedwith IPTG (+) to
express fusion ofGSTwith the indicatedVACVantigens. Proteins from thewhole cell lysateswere resolvedbySDS-PAGEand analyzedby either Coomassie staining or byWesternblotwith
the indicated antibody. (B) Western blot of puriﬁedWR mature virions.Mature virions were puriﬁed according to the standard protocol (Earl et al., 1998). Membrane-associated virion
proteins (Mem.)were extractedwith 0.5%NP-40 in the absence (−) or presence (+) of 50 mMDTT. Infected cells,whole virions or the fractionswere analyzed by SDS-PAGE andWestern
blot with the indicated antibody.
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blot a recombinant GST fusion protein of A33 among the bacterial cell
lysates (Fig. 4A), indicating that its target is A33.
Identiﬁcation of the antigen by protein ﬁnger-printing with mass
spectrometry
For the remaining hybridomas, we did not have the reagents for
testing our speciﬁc hypothesis, so we cross-linked the antibodies to
protein G sepharose, precipitated the antigens from infected cells and
identiﬁed them by mass spectrometry analysis.
Group 11(F13). CE7 precipitated a protein with an apparent MW of
38 kDa (Figs. 2 and 3C). The protein band shown in Fig. 3C was cut off
the gel, digested with trypsin, and analyzed with mass spectrometry.
10 peptide fragments of the protein matched that of F13, an EV
membrane protein. This identiﬁcation is consistent with immunoﬂu-
orescence pattern of CE7 (Fig. 1), which showed extensive staining of
areas outside viral factories and virion-size particles.Group 8(C3). Both AF9 and JB11 precipitated a protein with an
apparent MW of 27 kDa by SDS-PAGE (Figs. 2 and 3C). Mass
spectrometry ﬁnger-printing of the precipitated protein showed
that the protein is C3, the complement binding protein (Kotwal and
Moss, 1988).
Group 2(A14). A large group (group 2) of 17 hybridomas, including
GH3, precipitated a 15-kDa and a 23-kDa protein from metabolically-
labeled, WR-infected cells (Fig. 2). Coomassie staining of the proteins
that were precipitated by GH3 also detected the 15-kDa protein along
with additional other proteins (Fig. 3C). Most of the additional
proteins were also precipitated from uninfected cells, indicating that
they were host cell proteins, which were not metabolically-labeled in
VACV-infected cells but were nonspeciﬁcally precipitated. The 15-kDa
protein was initially tested for A27 (theoretical MW of 13 kDa), but it
was not recognized by anti-A27 rabbit antiserum (data not shown).
Protein ﬁnger-printing with mass spectrometry suggested that the
protein was A14, as a peptide fragment of this protein matched that of
A14. Indeed, GH3 speciﬁcally recognized the recombinant GST fusion
277X. Meng et al. / Virology 409 (2011) 271–279protein of A14 among the bacterial cell lysate in a Western
blot (Fig. 4A), indicating that its target is A14. This identiﬁcation is
consistent with the fact that group 2 hybridomas precipitated
the additional 23-kDa protein and stained the viral DNA factory
in immunoﬂuorescence (Figs. 1 and 2), as A14 is a MV membrane
protein that forms a disulﬁde-bonded dimer even under the
denaturing condition of SDS-PAGE (Mercer and Traktman, 2003). In
a Western blot of MV virion, GH3 detected both the 15-kDa and the
23-kDa proteins, which was most efﬁciently extracted from the virion
by the detergent NP-40 in combination with the reducing agent
DTT (Fig. 4B), consistent with the localization of A14 as a disulﬁde-
bonded dimer in MV membrane.
Group 10(A10). BG3 precipitated a protein that was close to 100 kDa
(Figs. 2 and 3C), which was identiﬁed by mass spectrometry to be
VACV A10 protein (theoretical MW of 102 kDa). Indeed, BG3
speciﬁcally recognized a recombinant GST fusion protein of A10
among the bacterial cell lysates in Western blot (Fig. 4A), conﬁrming
that its target is A10. During virion morphogenesis, the full-length
A10, also known as p4a, is proteolytically processed into three
fragments, and the N-terminal 62-kDa fragment, known as 4a, is
packaged into virion core as a major virion structural protein
(Vanslyke et al., 1991). In Western blot of puriﬁed virion, BG3
recognized the 62-kDa 4a protein (Fig. 4B), indicating that its epitope
is present within 4a. It was therefore surprising that BG3 mainly
precipitated p4a instead of 4a from infected cells. Upon examining a
longer exposure of the autoradiograph, we found that BG3 also
precipitated several smaller proteins of 60–75 kDa (Fig. 2), among
which could be the 4a protein. The reason why BG3 predominantly
precipitated p4a may be that 4a was tightly packaged into the virion
core and thus was less accessible for immunoprecipitation. Immuno-
ﬂuorescence with BG3 stained the viral factories and some virion-size
particles (Fig. 1), the latter of which could be uncoated virions in
newly infected cells. BG3 failed to recognize any protein in Western
blot of infected cell lysates (Fig. 4B), so its epitope may be
conformational, which was recognizable only when a large amount
of A10 protein was analyzed in Western blot.
Group 4(D13). Seven hybridomas, including AD4, precipitated a
protein of approximately 61 kDa (Figs. 2 and 3C), which was
identiﬁed by mass spectrometry to be D13 (theoretical MW of
62 kDa). Typical immunoﬂuorescence with this group of hybridomas
stained some viral factory as well as some aggregates in the cytoplasm
(Fig. 1).
Group 5(H3). JH4 and AE11 precipitated a protein with an apparent
MW of 32 kDa by SDS-PAGE (Figs. 2 and 3C), which was identiﬁed by
mass spectrometry to be the VACV MV membrane protein H3
(theoretical MW of 37 kDa). Immunoﬂuorescence with these hybri-
domas stained the viral factories and virion-size particles (Fig. 1),
consistent with MV membrane protein staining.
Discussion
We initiated the current study with the simple goal of generating
some monoclonal antibodies (mAbs) against VACV as reagents for
studying VACV biology. In the end, 66 mAbs against 11 different VACV
antigens were developed from a single immunized mouse. To our
knowledge, it is the ﬁrst time since 1980s that such a large number of
mAbs against such a diverse group of VACV proteins have been
reported. Several reports published decades ago had described a large
number of mAbs against VACV (Ichihashi and Oie, 1988; Wilton et al.,
1986). However, the antigenic targets of these mAbs were largely
unknown, and themAbs are no longer available. Ten years ago, a panel
of VACV-speciﬁc mAbs were generated by Alan Schmaljohn's group
(Hooper et al., 2000), but, unfortunately, they have never been fullydescribed in a publication. Nevertheless, some of the mAbs, including
a neutralizing antibody against L1, were made available to a few
groups and have been very useful in a number of studies (Lustig et al.,
2005). More recently, multiple mAbs against recombinant L1 and B5
proteins were generated from recombinant proteins by Cohen,
Eisenberg and co-workers (Aldaz-Carroll et al., 2005a,b), and these
mAbs have been very usefully in studies of MV and EV neutralization.
Here, we report for the ﬁrst time mAbs against A14, A10 and D13,
which are all proteins playing critical role in VACV morphogenesis.
The mAbs we generated in this study target nonstructural proteins
(WR148, D13L, and C3) as well as structural proteins in the virion core
(A10) or on the membranes of MV (D8, H3, and A14) or EV (B5, A33,
F13, and A56). Collectively, they make up an excellent molecular
“toolkit” for studying the life cycle of VACV.
We are pleasantly surprised with the number and the diversity of
the antibodies that we obtained from a single immunized mouse. This
success could perhaps be attributed to our immunization and
screening methodology. The mouse was initially infected with a live
attenuated VACV, which elicited an immune response that was strong
enough to protect against a subsequent high dose VACV challenge.
The mouse was ﬁnally given an intravenous dose of UV-inactivated
VACV three days before the harvest of the spleen. This immunization
scheme resulted in high titer of serum antibody against VACV and
ultimately led to a large number of hybridomas that are speciﬁc for
VACV. For screening the hybridomas, we performed immunoﬂuores-
cence assay of cells infected with VACV at low MOI. This method was
more labor-intensive than other commonly used methods such as
ELISA, but we found it to be highly speciﬁc and very sensitive. In our
hands, ELISA with infected cell lysate has a high percentage of false
positive, while ELISA with puriﬁed virus appears to only detect
antibody against major virion membrane proteins. In contrast,
immunoﬂuorescence of infected and uninfected cells in the same
slide unambiguously identiﬁed hybridomas that are speciﬁc for VACV.
In addition, cellular localization of the target proteins showed by
immunoﬂuorescence aided subsequent target identiﬁcation.
Although the immunization protocol that we used here differed
from the practice of smallpox vaccination, the spectrum of mAbs that
we generated matches nicely with the proﬁle of polyclonal antibody
response to smallpox vaccination (Davies et al., 2005a, 2007). A
proteome array of recombinant VACV proteins consistently detected
polyclonal antibodies to around 25 VACV proteins (Davies et al.,
2007), against 10 of which we have found hybridomas in this study.
For some VACV proteins that elicited strong polyclonal antibody
responses, including D8, A14, WR148 and D13, we found multiple
clones of hybridomas against the same protein. Therefore, the
spectrum of the hybridomas, which was generated and detected
with native VACV proteins, largely supports the polyclonal antibody
proﬁling done with recombinant proteins produced with a prokary-
otic system. There are some major targets of polyclonal antibodies,
against which we did not ﬁnd any hybridoma in this study. This may
be due partly to inherent limits in hybridoma generation and partly to
differences in antibody response to VACV in individual hosts. It was
shown that smallpox vaccination in humans could result in different
repertoire of antibody responses (Benhnia et al., 2008). On the other
hand, we found 2 hybridomas against C3, which was not detected by
the proteomic array as a polyclonal antibody target. C3 is the VACV
complement control protein (VCP), which is secreted by infected cells
and inhibits both the classical and the alternative pathways of
complement activation (Kotwal and Moss, 1988). Recently, two
studies showed that C3 is a target of vaccinia immune globulin (VIG)
(Adamo et al., 2009; Liszewski et al., 2009), whichwas harvested from
individuals vaccinated with smallpox vaccine. It is possible that the
proteome array failed to detect antibody response to C3 because the
C3 antibodies elicited by VACV only recognize native C3, which forms
intramolecular disulﬁde bonds in eukaryotic cells (Liszewski et al.,
2006). In addition to the advantage of detecting additional antibody
278 X. Meng et al. / Virology 409 (2011) 271–279response to native VACV proteins, our generation of hybridomas
resulted in monoclonal antibodies against a variety of VACV antigens,
which could be used to map B cell epitopes in smallpox vaccine
that contribute to immune protection.
Material and methods
Cells and viruses
BS-C-1 cells were maintained in minimum essential medium with
Earle's salts supplemented with 10% fetal bovine serum (FBS). HeLa
229 cells were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM) with 10% FBS. Wild-type (WT) and mutant WR viruses were
propagated on BS-C-1 cells. ΔA33R (vA33d) (Roper et al., 1998) and
ΔWR148 (v644) (Jones-Trower et al., 2005) mutant viruses were
obtained from Bernard Moss and Michael Merchlinsky, respectively.
ΔA56R was constructed by homologous recombination of WT WR
virus with a plasmid derived from pVote1 (Ward et al., 1995) using
standard protocols (Earl et al., 1998).
Hybridoma generation
A 4-week-old BALB/c mouse was infected intranasally with
105PFU of WR.K1L–C7L– (Meng et al., 2008), a highly attenuated
mutant of VACV WR with deletion in host-range genes K1L and C7L.
Two weeks later, the mouse was challenged with intranasal
inoculation of 4×106PFU of wild type (WT) VACV WR. The mouse
survived the challenge. After another 2 weeks, themousewas injected
intravenously with 7×107PFU of UV-inactivatedWR virus. Three days
later, the spleen of the mouse was harvested, the splenocytes fused
with the mouse myeloma SP2/0 cells, and the cells plated into 12 96-
well plates for selection, essentially as described before (Zhong et al.,
1997). After 14 days of selection, while most of the wells had no
colony, some had one or very rarely 2 colonies, which were
individually picked out of the wells.
Hybridoma screening
The hybridomaswere screened for their ability to secret anti-VACV
antibodies with an immunoﬂuorescence assay. Speciﬁcally, HeLa cells
grown on cover-slips were infected with VACV WR at 0.1 to 0.5 PFU/
cell for 8 h. The cells were ﬁxed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, blocked with DMEM with
10% FBS, and stained with 200 μl of the hybridoma supernatant
followed with a Cy3-conjugated secondary antibody and DAPI dye.
The slides were visualized with an AX-70 Olympus ﬂuorescence
microscope. The isotypes of the antibodies were determined by
immunoﬂuorescence or enzyme-linked immunosorbent assay
(ELISA) analysis of WR-infected cells with isotype-speciﬁc secondary
antibodies (Sigma-Aldrich).
Immunoprecipitation
HeLa cells in 100-mmdishes were infectedwithWTWR at 10 PFU/
cell. At 8 hpi, the culture medium was replaced with 5 ml of
methionine- and cysteine-free DMEM plus 100 μCi of 35S-methionine
and -cysteine per ml. After another 8 h, the cells were harvested
and lysed in a buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1%
Triton X-100, 0.1% SDS, and 0.5% sodiumdeoxycholate) supplemented
with protease inhibitor cocktail (RocheMolecular Biochemicals). 80 μl
of the cleared cell lysates was mixed with 1 ml of hybridoma
supernatant for 1 h, and then added with 30 μl of 50% (vol./vol.)
Protein G sepharose (GE Healthcare Life Sciences) and mixed for
another 1 h. The beads were washed consecutively with wash buffer
(0.1% [wt./vol.] Triton X-100, 50 mM Tris [pH 7.4], 300 mM NaCl, and
5 mM EDTA) and PBS before they were resuspended in SDS samplebuffer. The samples were analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) and autoradiography.
Western blot analysis
For results shown in Fig. 3A, hybridoma supernatants were used to
immunoprecipitate proteins as described earlier except that unla-
beled cells were used. The precipitated proteins were resolved by
SDS-PAGE and transferred to nitrocellulose membranes. The mem-
branes were blocked with 5% nonfat dried milk, incubated with rabbit
antisera against D8 or B5 (Sakhatskyy et al., 2006) followedwith anti-
rabbit secondary antibody, and analyzed with chemiluminescence
as described before (Meng and Xiang, 2006). For result shown in
Figs. 3B and 4, Western blot analysis was performed with undiluted
hybridoma supernatants as the primary antibodies.
Mass spectrometry
Antigens that were subjected to mass spectrometry analysis were
precipitated from WR-infected cells as described earlier with the
exception that, in most experiments, antibodies covalently-linked to
protein G sepharose were used for the precipitation. 30 μl of Protein G
sepharose was mixed with 1 ml of hybridoma supernatants for 1 h,
after which Bis(Sulfosuccinimidyl)-suberate (Pierce) was added to
cross-link the antibody to the sepharose. The precipitated proteins
were resolved by SDS-PAGE and stained with Coomassie blue dye.
Individual bands were cut off the gel, digested with trypsin and
analyzed with mass spectrometry by mass spectrometry core facility
at UTHSCSA.
Expression of recombinant proteins
The plasmids for expressing the fusion of GST and various viral
proteins were constructed by PCR amplifying the viral gene from WR
DNA and cloned the PCR fragment into pGEX6P-1 (GE Healthcare Life
Sciences) using the NcoI and BamHI sites. The expression of the fusion
protein in E. coli BL21 strain was induced with isopropyl-beta-D-
thiogalactoside (IPTG; Invitrogen). The bacteria were harvested and
lyzed via sonication in SDS-PAGE sample buffer. The clariﬁed cell
lysates were then used in Western blot analysis.
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